Latest News and Press Releases
Want to stay updated on the latest news?
-
LONDON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 7th Annual Evercore ISI...
-
LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 2024 Jefferies London...
-
– ARCALYST® (rilonacept) Q3 2024 net product revenue of $112.2 million, representing 73% year-over-year growth –– ARCALYST 2024 expected net product revenue increased to $410 - $420 million –– Life...
-
– National campaign to elevate experiences from the recurrent pericarditis community and empower patients to seek care – LONDON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals...
-
LONDON, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 29, 2024...
-
LONDON, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company, has teamed up with National Hockey...
-
LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 2024 Wells Fargo...
-
Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution
– ARCALYST® (rilonacept) Q2 2024 net product revenue of $103.4 million, representing 90% year-over-year growth –– ARCALYST 2024 expected net product revenue increased to $405 - $415 million...
-
LONDON, July 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 23, 2024 at...
-
– Abiprubart Phase 2b clinical trial in Sjögren’s Disease to evaluate treatment response across biweekly and monthly subcutaneous administrations – – Abiprubart clinical development in Sjögren’s...